Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.54 |
| ▸ | HTR7 | P34969 | 3/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27980806 | 1.00 | SIGMAR1 (0.54) | SIGMAR1HTR7KDM1AOPRM1ACKR3 | |
| SCHEMBL7971782 | 0.87 | SIGMAR1 (0.69) | SIGMAR1HTR7OPRM1ACKR3ADORA3 | |
| SCHEMBL2194827 | 0.85 | KDM1A (0.57) | KDM1ACHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL30812262 | 0.83 | GPR119 (0.51) | KDM1A | |
| SCHEMBL7989733 | 0.82 | SIGMAR1 (0.64) | SIGMAR1HTR7OPRM1ACKR3ADORA3 | |
| SCHEMBL7160444 | 0.81 | KDM1A (0.52) | SIGMAR1KDM1ACHRM2CHRM4CHRM1 | |
| SCHEMBL1744477 | 0.81 | SIGMAR1 (0.50) | SIGMAR1HTR7OPRM1ACKR3ADORA3 | |
| SCHEMBL15103054 | 0.81 | KDM4E (0.55) | SIGMAR1HTR7OPRM1ACKR3ADORA3 | |
| SCHEMBL2378962 | 0.80 | SIGMAR1 (0.49) | SIGMAR1ACKR3HTR2ACHRM2CHRM4 | |
| SCHEMBL30812113 | 0.80 | EPHX2 (0.60) | CHRM2CHRM4CHRM1CHRM3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | BRD4, BRDT, BICRA | SIGMAR1 801/4885HTR7 1529/4885KDM1A 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.